<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34115705</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-0229</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical nuclear medicine</Title><ISOAbbreviation>Clin Nucl Med</ISOAbbreviation></Journal><ArticleTitle>18F-THK5351 PET Can Identify Core Lesions in Different Amyotrophic Lateral Sclerosis Phenotypes.</ArticleTitle><Pagination><StartPage>e582</StartPage><EndPage>e583</EndPage><MedlinePgn>e582-e583</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/RLU.0000000000003755</ELocationID><Abstract><AbstractText>Two patients with different amyotrophic lateral sclerosis (ALS) phenotypes underwent 18F-THK5351 PET to visualize lesions undergoing astrogliosis by measuring monoamine oxidase B activity. Patient 1 was a 57-year-old man with flail leg syndrome. Elevated uptake was observed inside the motor cortex, corresponding to the leg area in a cortical homunculus. Patient 2 was a 64-year-old man with ALS-frontotemporal dementia semantic variant. Elevated uptake was observed around the left anterior temporal lobe. Both core lesions were consistent with their respective neurological features. Hence, 18F-THK5351 PET is a useful technique to assess ALS pathophysiology by visualizing the core lesions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Higashihara</LastName><ForeName>Mana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, Tokyo Metropolitan Geriatric Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishibashi</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Tokumaru</LastName><ForeName>Aya M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, Tokyo Metropolitan Geriatric Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Nucl Med</MedlineTA><NlmUniqueID>7611109</NlmUniqueID><ISSNLinking>0363-9762</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000631">Aminopyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011804">Quinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000608225">THK5351</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000631" MajorTopicYN="N">Aminopyridines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of interest and sources of funding: none declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>11</Day><Hour>17</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34115705</ArticleId><ArticleId IdType="doi">10.1097/RLU.0000000000003755</ArticleId><ArticleId IdType="pii">00003072-202112000-00035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ng KP, Pascoal TA, Mathotaarachchi S, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18 F-THK5351 uptake in the human brain. Alzheimers Res Ther . 2017;9:25.</Citation></Reference><Reference><Citation>Harada R, Ishiki A, Kai H, et al. Correlations of (18)F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease. J Nucl Med . 2018;59:671&#x2013;674.</Citation></Reference><Reference><Citation>Tago T, Toyohara J, Sengoku R, et al. Monoamine oxidase B binding of 18 F-THK5351 to visualize glioblastoma and associated gliosis: an autopsy-confirmed case. Clin Nucl Med . 2019;44:507&#x2013;509.</Citation></Reference><Reference><Citation>Lerdsirisuk P, Harada R, Hayakawa Y, et al. Synthesis and evaluation of 2-pyrrolopyridinylquinoline derivatives as selective tau PET tracers for the diagnosis of Alzheimer&#x2019;s disease. Nucl Med Biol . 2020;93:11&#x2013;18.</Citation></Reference><Reference><Citation>Saura J, Bleuel Z, Ulrich J, et al. Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience . 1996;70:755&#x2013;774.</Citation></Reference><Reference><Citation>Ishibashi K, Kameyama M, Tago T, et al. Potential use of 18 F-THK5351 PET to identify wallerian degeneration of the pyramidal tract caused by cerebral infarction. Clin Nucl Med . 2017;42:e523&#x2013;e524.</Citation></Reference><Reference><Citation>Ishibashi K, Miura Y, Hirata K, et al. 18 F-THK5351 PET can identify astrogliosis in multiple sclerosis plaques. Clin Nucl Med . 2020;45:e98&#x2013;e100.</Citation></Reference><Reference><Citation>Ishibashi K, Miura Y, Hirata K, et al. Relationship between the temporal course of astrogliosis and symptom improvement in cerebral infarction: report of a case monitored using (18)F-THK5351 positron emission tomography. BMC Med Imaging . 2020;20:81.</Citation></Reference><Reference><Citation>Ishibashi K, Kameyama M, Miura Y, et al. Head-to-head comparison of the two MAO-B radioligands, 18 F-THK5351 and 11 C-L-Deprenyl, to visualize astrogliosis in patients with neurological disorders. Clin Nucl Med . 2021;46:e31&#x2013;e33.</Citation></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol . 2014;10:661&#x2013;670.</Citation></Reference><Reference><Citation>Barbeito LH, Pehar M, Cassina P, et al. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev . 2004;47:263&#x2013;274.</Citation></Reference><Reference><Citation>Kawakami I, Arai T, Hasegawa M. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol . 2019;138:751&#x2013;770.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>